Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Colorectal Neoplasms

Free Subscription Articles published in Oncogene Retrieve available abstracts of 75 articles: HTML format

Single Articles

March 2023
1. ZHANG X, Ma D, Xuan B, Shi D, et al
   LncRNA CACClnc promotes chemoresistance of colorectal cancer by modulating alternative splicing of RAD51.
   Oncogene. 2023 Mar 11. doi: 10.1038/s41388-023-02657.
   PubMed     Abstract available
   
   
   
2. HUANG S, Li J, Wu S, Zheng Z, et al
   C4orf19 inhibits colorectal cancer cell proliferation by competitively binding to Keap1 with TRIM25 via the USP17/Elk-1/CDK6 axis.
   Oncogene. 2023 Mar 7. doi: 10.1038/s41388-023-02656.
   PubMed     Abstract available
   
   
   
3. TABATA S, Kojima Y, Sakamoto T, Igarashi K, et al
   L-2hydroxyglutaric acid rewires amino acid metabolism in colorectal cancer via the mTOR-ATF4 axis.
   Oncogene. 2023 Mar 6. doi: 10.1038/s41388-023-02632.
   PubMed     Abstract available
   
   
   
4. CHEN Y, Qiu Q, She J, Yu J, et al
   Extrachromosomal circular DNA in colorectal cancer: biogenesis, function and potential as therapeutic target.
   Oncogene. 2023 Mar 1. doi: 10.1038/s41388-023-02640.
   PubMed     Abstract available
   
   
   January 2023
5. TONG J, Tan X, Hao S, Ermine K, et al
   Inhibition of multiple CDKs potentiates colon cancer chemotherapy via p73-mediated DR5 induction.
   Oncogene. 2023 Jan 31. doi: 10.1038/s41388-023-02598.
   PubMed     Abstract available
   
   
   December 2022
6. WANG T, Jin C, Yang P, Chen Z, et al
   UBE2J1 inhibits colorectal cancer progression by promoting ubiquitination and degradation of RPS3.
   Oncogene. 2022 Dec 26. doi: 10.1038/s41388-022-02581.
   PubMed     Abstract available
   
   
   
7. QIAN Y, Zhou L, Luk STY, Xu J, et al
   The sodium channel subunit SCNN1B suppresses colorectal cancer via suppression of active c-Raf and MAPK signaling cascade.
   Oncogene. 2022 Dec 23. doi: 10.1038/s41388-022-02576.
   PubMed     Abstract available
   
   
   
8. SHI F, Liu G, Lin Y, Guo CL, et al
   Altered gut microbiome composition by appendectomy contributes to colorectal cancer.
   Oncogene. 2022 Dec 20. doi: 10.1038/s41388-022-02569.
   PubMed     Abstract available
   
   
   
9. CARTON-GARCIA F, Brotons B, Anguita E, Dopeso H, et al
   Myosin Vb as a tumor suppressor gene in intestinal cancer.
   Oncogene. 2022;41:5279-5288.
   PubMed     Abstract available
   
   
   November 2022
10. FU Z, Zhang P, Zhang R, Zhang B, et al
    Novel hypoxia-induced HIF1alpha-circTDRD3-positive feedback loop promotes the growth and metastasis of colorectal cancer.
    Oncogene. 2022 Nov 22. doi: 10.1038/s41388-022-02548.
    PubMed     Abstract available
    
    
    
11. SONG F, Zhang Y, Chen Q, Bi D, et al
    Mast cells inhibit colorectal cancer development by inducing ER stress through secreting Cystatin C.
    Oncogene. 2022 Nov 19. doi: 10.1038/s41388-022-02543.
    PubMed     Abstract available
    
    
    
12. XU C, Gu L, Kuerbanjiang M, Jiang C, et al
    Adaptive activation of EFNB2/EPHB4 axis promotes post-metastatic growth of colorectal cancer liver metastases by LDLR-mediated cholesterol uptake.
    Oncogene. 2022 Nov 14. pii: 10.1038/s41388-022-02519.
    PubMed     Abstract available
    
    
    
13. CUI K, Gong L, Zhang H, Chen Y, et al
    EXOSC8 promotes colorectal cancer tumorigenesis via regulating ribosome biogenesis-related processes.
    Oncogene. 2022 Nov 8. pii: 10.1038/s41388-022-02530.
    PubMed     Abstract available
    
    
    
14. KLOUCH KZ, Stern MH, Trabelsi-Grati O, Kiavue N, et al
    Microsatellite instability detection in breast cancer using drop-off droplet digital PCR.
    Oncogene. 2022 Nov 3. pii: 10.1038/s41388-022-02504.
    PubMed     Abstract available
    
    
    October 2022
15. WANG YN, Ruan DY, Wang ZX, Yu K, et al
    Targeting the cholesterol-RORalpha/gamma axis inhibits colorectal cancer progression through degrading c-myc.
    Oncogene. 2022 Oct 31. pii: 10.1038/s41388-022-02515.
    PubMed     Abstract available
    
    
    
16. ZHANG X, Hu F, Zhu B, Jiao X, et al
    Downregulation of TEX11 promotes S-Phase progression and proliferation in colorectal cancer cells through the FOXO3a/COP1/c-Jun/p21 axis.
    Oncogene. 2022 Oct 18. pii: 10.1038/s41388-022-02490.
    PubMed     Abstract available
    
    
    
17. PENG X, Na R, Zhou W, Meng X, et al
    Nuclear translocation of Gasdermin D sensitizes colorectal cancer to chemotherapy in a pyroptosis-independent manner.
    Oncogene. 2022 Oct 16. pii: 10.1038/s41388-022-02503.
    PubMed     Abstract available
    
    
    
18. BATTAGLIN F, Jayachandran P, Strelez C, Lenz A, et al
    Neurotransmitter signaling: a new frontier in colorectal cancer biology and treatment.
    Oncogene. 2022 Oct 1. pii: 10.1038/s41388-022-02479.
    PubMed     Abstract available
    
    
    September 2022
19. MENG X, Peng J, Xie X, Yu F, et al
    Roles of lncRNA LVBU in regulating urea cycle/polyamine synthesis axis to promote colorectal carcinoma progression.
    Oncogene. 2022;41:4231-4243.
    PubMed     Abstract available
    
    
    
20. KORTUM B, Radhakrishnan H, Zincke F, Sachse C, et al
    Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-beta-catenin-S100A4 axis of metastasis.
    Oncogene. 2022;41:4446-4458.
    PubMed     Abstract available
    
    
    August 2022
21. LING H, Cao CH, Han K, Lv YR, et al
    CEP63 upregulates YAP1 to promote colorectal cancer progression through stabilizing RNA binding protein FXR1.
    Oncogene. 2022 Aug 22. pii: 10.1038/s41388-022-02439.
    PubMed     Abstract available
    
    
    
22. ZHOU B, Zong S, Zhong W, Tian Y, et al
    Correction: Interaction between laminin-5gamma2 and integrin beta1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins.
    Oncogene. 2022 Aug 12. pii: 10.1038/s41388-022-02422.
    PubMed    
    
    
    
23. MOUILLET-RICHARD S, Martin-Lanneree S, Le Corre D, Hirsch TZ, et al
    A proof of concept for targeting the PrP(C) - Amyloid beta peptide interaction in basal prostate cancer and mesenchymal colon cancer.
    Oncogene. 2022 Aug 12. pii: 10.1038/s41388-022-02430.
    PubMed     Abstract available
    
    
    
24. HORIGUCHI H, Kadomatsu T, Yumoto S, Masuda T, et al
    Tumor cell-derived ANGPTL2 promotes beta-catenin-driven intestinal tumorigenesis.
    Oncogene. 2022;41:4028-4041.
    PubMed     Abstract available
    
    
    July 2022
25. ZHAO L, Zhang X, Zhou Y, Fu K, et al
    Parvimonas micra promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients.
    Oncogene. 2022 Jul 27. pii: 10.1038/s41388-022-02395.
    PubMed     Abstract available
    
    
    
26. YOU A, Tian W, Yuan H, Gu L, et al
    TTC22 promotes m6A-mediated WTAP expression and colon cancer metastasis in an RPL4 binding-dependent pattern.
    Oncogene. 2022 Jul 7. pii: 10.1038/s41388-022-02402.
    PubMed     Abstract available
    
    
    June 2022
27. PUCCINI A, Poorman K, Catalano F, Seeber A, et al
    Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets.
    Oncogene. 2022;41:3455-3460.
    PubMed     Abstract available
    
    
    May 2022
28. CHEN Y, Zhou S, Wan K, Yu L, et al
    RIOK1 mediates p53 degradation and radioresistance in colorectal cancer through phosphorylation of G3BP2.
    Oncogene. 2022 May 19. pii: 10.1038/s41388-022-02352.
    PubMed     Abstract available
    
    
    
29. YANG L, WenTao T, ZhiYuan Z, Qi L, et al
    Cullin-9/p53 mediates HNRNPC degradation to inhibit erastin-induced ferroptosis and is blocked by MDM2 inhibition in colorectal cancer.
    Oncogene. 2022 May 3. pii: 10.1038/s41388-022-02284.
    PubMed     Abstract available
    
    
    April 2022
30. CHEN Z, Zhang X, Xing Z, Lv S, et al
    OLFM4 deficiency delays the progression of colitis to colorectal cancer by abrogating PMN-MDSCs recruitment.
    Oncogene. 2022 Apr 29. pii: 10.1038/s41388-022-02324.
    PubMed     Abstract available
    
    
    
31. GUO P, Chen Q, Peng K, Xie J, et al
    Nuclear receptor coactivator SRC-1 promotes colorectal cancer progression through enhancing GLI2-mediated Hedgehog signaling.
    Oncogene. 2022 Apr 13. pii: 10.1038/s41388-022-02308.
    PubMed     Abstract available
    
    
    
32. SHI C, Tao S, Ren G, Yang EJ, et al
    Aurora kinase A inhibition induces synthetic lethality in SMAD4-deficient colorectal cancer cells via spindle assembly checkpoint activation.
    Oncogene. 2022 Apr 7. pii: 10.1038/s41388-022-02293.
    PubMed     Abstract available
    
    
    
33. CUI YM, Jiao HL, Ye YP, Chen CM, et al
    Retraction Note to: FOXC2 promotes colorectal cancer metastasis by directly targeting MET.
    Oncogene. 2022 Apr 1. pii: 10.1038/s41388-022-02287.
    PubMed    
    
    
    
34. BAKER K, O'Donnell C, Bendix M, Keogh S, et al
    IL-36 signalling enhances a pro-tumorigenic phenotype in colon cancer cells with cancer cell growth restricted by administration of the IL-36R antagonist.
    Oncogene. 2022 Apr 1. pii: 10.1038/s41388-022-02281.
    PubMed     Abstract available
    
    
    
35. MAGRIN L, Fanale D, Brando C, Corsini LR, et al
    MUTYH-associated tumor syndrome: The other face of MAP.
    Oncogene. 2022;41:2531-2539.
    PubMed     Abstract available
    
    
    March 2022
36. RAO VS, Gu Q, Tzschentke S, Lin K, et al
    Extravesicular TIMP-1 is a non-invasive independent prognostic marker and potential therapeutic target in colorectal liver metastases.
    Oncogene. 2022;41:1809-1820.
    PubMed     Abstract available
    
    
    
37. FLUM M, Dicks S, Teng YH, Schrempp M, et al
    Canonical TGFbeta signaling induces collective invasion in colorectal carcinogenesis through a Snail1- and Zeb1-independent partial EMT.
    Oncogene. 2022;41:1492-1506.
    PubMed     Abstract available
    
    
    February 2022
38. QIAO G, Kone LB, Phillips EH, Lee SS, et al
    LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer.
    Oncogene. 2022 Feb 17. pii: 10.1038/s41388-022-02209.
    PubMed     Abstract available
    
    
    
39. PARK YL, Kim HP, Ock CY, Min DW, et al
    EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer.
    Oncogene. 2022 Feb 16. pii: 10.1038/s41388-021-01920.
    PubMed     Abstract available
    
    
    
40. WU H, Ding X, Hu X, Zhao Q, et al
    LINC01021 maintains tumorigenicity by enhancing N6-methyladenosine reader IMP2 dependent stabilization of MSX1 and JARID2: implication in colorectal cancer.
    Oncogene. 2022 Feb 16. pii: 10.1038/s41388-022-02189.
    PubMed     Abstract available
    
    
    
41. LI B, Kang H, Xiao Y, Du Y, et al
    LncRNA GAL promotes colorectal cancer liver metastasis through stabilizing GLUT1.
    Oncogene. 2022 Feb 11. pii: 10.1038/s41388-022-02230.
    PubMed     Abstract available
    
    
    
42. GUERRA E, Relli V, Ceci M, Tripaldi R, et al
    Trop-2, Na(+)/K(+) ATPase, CD9, PKCalpha, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion.
    Oncogene. 2022 Feb 7. pii: 10.1038/s41388-022-02220.
    PubMed     Abstract available
    
    
    January 2022
43. SALIBA J, Coutaud B, Makhani K, Epstein Roth N, et al
    Loss of NFE2L3 protects against inflammation-induced colorectal cancer through modulation of the tumor microenvironment.
    Oncogene. 2022 Jan 28. pii: 10.1038/s41388-022-02192.
    PubMed     Abstract available
    
    
    
44. HE XS, Ye WL, Zhang YJ, Yang XQ, et al
    Oncogenic potential of BEST4 in colorectal cancer via activation of PI3K/Akt signaling.
    Oncogene. 2022 Jan 21. pii: 10.1038/s41388-021-02160.
    PubMed     Abstract available
    
    
    
45. CHEN Q, Zhuang S, Hong Y, Yang L, et al
    Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling.
    Oncogene. 2022 Jan 14. pii: 10.1038/s41388-021-02173.
    PubMed     Abstract available
    
    
    
46. LIN J, Xia L, Oyang L, Liang J, et al
    The POU2F1-ALDOA axis promotes the proliferation and chemoresistance of colon cancer cells by enhancing glycolysis and the pentose phosphate pathway activity.
    Oncogene. 2022 Jan 8. pii: 10.1038/s41388-021-02148.
    PubMed     Abstract available
    
    
    
47. ZHENG D, Cao M, Zuo S, Xia X, et al
    Correction: RANBP1 promotes colorectal cancer progression by regulating pre-miRNA nuclear export via a positive feedback loop with YAP.
    Oncogene. 2022 Jan 4. pii: 10.1038/s41388-021-02152.
    PubMed    
    
    
    December 2021
48. FREY P, Devisme A, Rose K, Schrempp M, et al
    SMAD4 mutations do not preclude epithelial-mesenchymal transition in colorectal cancer.
    Oncogene. 2021 Dec 3. pii: 10.1038/s41388-021-02128.
    PubMed     Abstract available
    
    
    
49. LI Z, He Y, Li Y, Li J, et al
    NeuroD1 promotes tumor cell proliferation and tumorigenesis by directly activating the pentose phosphate pathway in colorectal carcinoma.
    Oncogene. 2021;40:6736-6747.
    PubMed     Abstract available
    
    
    
50. CAO CH, Ling H, Han K, Lu XP, et al
    PPIP5K2 promotes colorectal carcinoma pathogenesis through facilitating DNA homologous recombination repair.
    Oncogene. 2021;40:6680-6691.
    PubMed     Abstract available
    
    
    
51. WANG S, Wong CC, Zhang Y, Huang J, et al
    ZNF545 loss promotes ribosome biogenesis and protein translation to initiate colorectal tumorigenesis in mice.
    Oncogene. 2021;40:6590-6600.
    PubMed     Abstract available
    
    
    November 2021
52. VERY N, Hardiville S, Decourcelle A, Thevenet J, et al
    Thymidylate synthase O-GlcNAcylation: a molecular mechanism of 5-FU sensitization in colorectal cancer.
    Oncogene. 2021 Nov 29. pii: 10.1038/s41388-021-02121.
    PubMed     Abstract available
    
    
    
53. MA L, Lin Y, Sun SW, Xu J, et al
    KIAA1429 is a potential prognostic marker in colorectal cancer by promoting the proliferation via downregulating WEE1 expression in an m6A-independent manner.
    Oncogene. 2021 Nov 24. pii: 10.1038/s41388-021-02066.
    PubMed     Abstract available
    
    
    
54. HAN F, Zhang L, Liao S, Zhang Y, et al
    The interaction between S100A2 and KPNA2 mediates NFYA nuclear import and is a novel therapeutic target for colorectal cancer metastasis.
    Oncogene. 2021 Nov 20. pii: 10.1038/s41388-021-02116.
    PubMed     Abstract available
    
    
    
55. HE F, Song Z, Chen H, Chen Z, et al
    Correction: Long noncoding RNA PVT1-214 promotes proliferation and invasion of colorectal cancer by stabilizing Lin28 and interacting with miR-128.
    Oncogene. 2021 Nov 9. pii: 10.1038/s41388-021-02093.
    PubMed    
    
    
    
56. ARAI H, Elliott A, Millstein J, Xiu J, et al
    Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.
    Oncogene. 2021 Nov 2. pii: 10.1038/s41388-021-02074.
    PubMed     Abstract available
    
    
    
57. POLOSUKHINA D, Singh K, Asim M, Barry DP, et al
    CCL11 exacerbates colitis and inflammation-associated colon tumorigenesis.
    Oncogene. 2021;40:6540-6546.
    PubMed     Abstract available
    
    
    
58. XU H, Wong CC, Li W, Zhou Y, et al
    RING-finger protein 6 promotes colorectal tumorigenesis by transcriptionally activating SF3B2.
    Oncogene. 2021;40:6513-6526.
    PubMed     Abstract available
    
    
    October 2021
59. YU C, Luo D, Yu J, Zhang M, et al
    Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer.
    Oncogene. 2021 Oct 30. pii: 10.1038/s41388-021-02077.
    PubMed     Abstract available
    
    
    
60. YU S, Zang W, Qiu Y, Liao L, et al
    Deubiquitinase OTUB2 exacerbates the progression of colorectal cancer by promoting PKM2 activity and glycolysis.
    Oncogene. 2021 Oct 20. pii: 10.1038/s41388-021-02071.
    PubMed     Abstract available
    
    
    
61. ZHANG J, Zhai J, Wong CC, Chen H, et al
    A novel amplification gene PCI domain containing 2 (PCID2) promotes colorectal cancer through directly degrading a tumor suppressor promyelocytic leukemia (PML).
    Oncogene. 2021 Oct 8. pii: 10.1038/s41388-021-01941.
    PubMed     Abstract available
    
    
    
62. GAO S, Soares F, Wang S, Wong CC, et al
    CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer.
    Oncogene. 2021 Oct 7. pii: 10.1038/s41388-021-01882.
    PubMed     Abstract available
    
    
    
63. ZHENG D, Cao M, Zuo S, Xia X, et al
    RANBP1 promotes colorectal cancer progression by regulating pre-miRNA nuclear export via a positive feedback loop with YAP.
    Oncogene. 2021 Oct 6. pii: 10.1038/s41388-021-02036.
    PubMed     Abstract available
    
    
    
64. TONG J, Tan X, Risnik D, Gao M, et al
    BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade.
    Oncogene. 2021 Oct 6. pii: 10.1038/s41388-021-02041.
    PubMed     Abstract available
    
    
    
65. HUA Q, Zhang B, Xu G, Wang L, et al
    CEMIP, a novel adaptor protein of OGT, promotes colorectal cancer metastasis through glutamine metabolic reprogramming via reciprocal regulation of beta-catenin.
    Oncogene. 2021 Oct 4. pii: 10.1038/s41388-021-02023.
    PubMed     Abstract available
    
    
    
66. TONG K, Kothari OA, Haro KS, Panda A, et al
    SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis.
    Oncogene. 2021;40:6034-6048.
    PubMed     Abstract available
    
    
    
67. CHEN L, Jin XH, Luo J, Duan JL, et al
    ITLN1 inhibits tumor neovascularization and myeloid derived suppressor cells accumulation in colorectal carcinoma.
    Oncogene. 2021;40:5925-5937.
    PubMed     Abstract available
    
    
    September 2021
68. ZHANG W, Pan R, Lu M, Zhang Q, et al
    Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin beta3/SRC pathway.
    Oncogene. 2021 Sep 29. pii: 10.1038/s41388-021-02029.
    PubMed     Abstract available
    
    
    August 2021
69. LIEBS S, Eder T, Klauschen F, Schutte M, et al
    Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities.
    Oncogene. 2021;40:5204-5212.
    PubMed     Abstract available
    
    
    May 2021
70. JUNG HR, Oh Y, Na D, Min S, et al
    CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers.
    Oncogene. 2021;40:3287-3302.
    PubMed     Abstract available
    
    
    April 2021
71. SONG D, Lan J, Chen Y, Liu A, et al
    NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein.
    Oncogene. 2021;40:2952-2967.
    PubMed     Abstract available
    
    
    
72. MANTILLA-ROJAS C, Yu M, Rinella ES, Lynch RM, et al
    A molecular subtype of colorectal cancers initiates independently of epidermal growth factor receptor and has an accelerated growth rate mediated by IL10-dependent anergy.
    Oncogene. 2021;40:3047-3059.
    PubMed     Abstract available
    
    
    
73. MA H, Zhang F, Zhou L, Cao T, et al
    c-Src facilitates tumorigenesis by phosphorylating and activating G6PD.
    Oncogene. 2021;40:2567-2580.
    PubMed     Abstract available
    
    
    March 2021
74. GOLLAVILLI PN, Parma B, Siddiqui A, Yang H, et al
    The role of miR-200b/c in balancing EMT and proliferation revealed by an activity reporter.
    Oncogene. 2021;40:2309-2322.
    PubMed     Abstract available
    
    
    
75. FLETCHER R, Tong J, Risnik D, Leibowitz BJ, et al
    Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis.
    Oncogene. 2021;40:2035-2050.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: